Factual and Procedural Background
This case involves litigation between two large international organisations concerned with tobacco products, referred to here as Company A and Company B. The dispute concerns technology related to reduced risk products (RRP) or tobacco heated products (THP), devices that heat tobacco rather than burn it to release flavour and nicotine.
There are two sets of patents at issue: the "Robinson" patents with a priority date in 2006, including UK patents EP (UK) 3 398 460 and 3 491 944; and the "Greim" patents, a family of four divisionals with a 2009 priority date, including EP (UK) 3 248 484, 3 248 486, and 3 248 483. Both sets relate broadly to heating devices in RRPs and related aspects.
Company A’s evidence includes witness statements from a solicitor and the Managing Director of its UK entity. Company B’s evidence includes witness statements from a solicitor instructed by its group.
One of the earliest Greim patents was granted in May 2019, and the '460 Robinson patent was granted in July 2019, with the opposition period for the latter expiring in April 2020.
On 9 April 2020, Company B initiated two sets of legal proceedings in Europe: an infringement action in Germany against Company A relating to the '460 patent and an invalidity action in the UK concerning some of Company A’s Greim patents. Around 15 April, Company B also started proceedings in the US, and there have been prior international patent disputes between these parties.
On 15 April, Company A brought an invalidity action in the UK relating to the '460 patent and an infringement counterclaim concerning the Greim patents against Company B’s product known as "glo".
The application before the court was by Company A to expedite the '460 Robinson patent litigation in the UK, seeking a trial date around January or February 2021. Company B opposed this but requested that if expedition was granted for the Robinson case, the Greim litigation should also be expedited.
Legal Issues Presented
- Whether there is a good reason to grant expedition of the '460 Robinson patent litigation in the UK.
- Whether, if expedition is granted for the Robinson case, the Greim litigation should also be expedited.
Arguments of the Parties
Company A's Arguments
- The UK trial for the Robinson patent should be expedited to occur before the German infringement trial scheduled for February 2021 to provide commercial certainty.
- The IQOS UK market is growing and critical investment decisions must be made in early 2021 regarding branding and third-party relationships, necessitating an expedited trial.
- Alternative products to IQOS have not been commercialised and would be a backward step, so the outcome of this patent dispute directly affects investment decisions.
Company B's Arguments
- Company A’s major income in the UK is still from traditional cigarettes; the IQOS market is currently small.
- The UK is a relatively small market globally for these products, so expedition is not justified on that basis.
- Company A has alternative products, so investment decisions are not solely dependent on the IQOS patent dispute.
- Company A has known about the '460 patent for over a year, so the risk was factored in before litigation began.
- If expedition is granted for the Robinson case, the Greim litigation should also be expedited to assist with Company B’s international decision-making.
Table of Precedents Cited
| Precedent |
Rule or Principle Cited For |
Application by the Court |
| James Petter v EMC Europe Limited [2015] EWCA Civ 480 |
Framework for considering applications for expedition, including restating principles from Gore v Geox. |
The court applied the four-factor test for expedition and emphasized the need for a "good reason" supported by evidence. |
| Gore v Geox |
Four factors to consider in expedition applications. |
Formed the basis of the court’s analytical framework for deciding whether to expedite the trial. |
| Daltel Europe Ltd (In Liquidation) v Makki [2004] EWHC 1631 (Ch) |
Need for real urgency as justification for expedition. |
Reinforced the requirement that there must be genuine urgency to justify expedition. |
| Eli Lilly & Company v Human Genome Sciences [2012] EWHC 2857 (Pat) |
Recognition that many litigants seek expedition, so good reasons must be established. |
Supported the court’s approach to not grant expedition lightly or simply because a party desires it. |
| HTC Europe Ltd v Apple Inc [2011] EWHC 2396 (Pat), ZTE (UK) Limited v Telegonaktiebolaget LM Ericsson [2011] EWHC 2709 (Pat), Garmin (Europe) Limited v Koninklijke Philips N.V. [2017] EWHC 8165 (Pat) |
Consideration of parallel proceedings and the limited weight of this factor alone in expedition decisions. |
The court acknowledged this as a factor but not sufficient alone to justify expedition. |
| Takeda UK Ltd v F Hoffmann-La Roche Ag [2018] EWHC 2155 |
Importance of UK court decisions influencing German courts in parallel patent litigation. |
The court accepted that UK trial timing can be relevant to parallel German proceedings but is not determinative alone. |
Court's Reasoning and Analysis
The court began by applying the established four-factor test from Gore v Geox, as restated in James Petter, to assess the application for expedition. The factors considered included the administration of justice, prejudice to the parties, special factors, and the presence of a good reason for expedition.
The court noted that the trial could be accommodated in January or February 2021 without significant disruption to the court’s list, and that the degree of expedition sought was moderate rather than extreme.
In considering prejudice, the court found no real prejudice to Company B in advancing the trial date, with concerns about experiments and evidence being manageable through disclosure.
No special factors were identified beyond the need to establish a good reason for expedition.
The court gave particular weight to the commercial context presented by Company A, including the growing UK market for the IQOS product and the need for timely investment decisions affecting both the group and third parties. The court rejected Company B’s argument that alternative products made the patent dispute irrelevant to investment decisions, finding that IQOS was the primary product planned for launch.
The court also accepted that the initiation of litigation in Germany increased the urgency for Company A to have certainty in the UK trial, distinguishing this from the prior knowledge of the patent without active litigation.
Regarding the request to expedite the Greim litigation, the court found that the reasons advanced by Company B did not meet the threshold for expedition. The Greim case related to past acts and damages claims, with no ongoing UK business, and no compelling evidence was presented to justify advancing the trial date.
Finally, the court addressed costs, finding the solicitors’ time claimed to be excessive and reducing the recoverable amount accordingly, while leaving counsel’s fees unchanged.
Holding and Implications
The court GRANTED the application to expedite the '460 Robinson patent litigation, ordering that the trial be scheduled for January or February 2021. This decision was based on the demonstrated real urgency and commercial reasons presented by Company A, balanced against the absence of serious prejudice or disruption.
The court REFUSED the application to expedite the Greim litigation, finding insufficient justification to move the trial date earlier than the normal listing window.
The direct effect of this decision is to advance the Robinson patent trial to an earlier date, providing Company A with greater commercial certainty before the parallel German infringement trial. No new legal precedent was established; the court applied established principles concerning expedition and commercial urgency.